Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2025)

Vivos Therapeutics has reported Current Deferred Revenue over the past 7 years, most recently at $479000.0 for Q4 2025.

  • Quarterly Current Deferred Revenue fell 46.54% to $479000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $479000.0 through Dec 2025, down 46.54% year-over-year, with the annual reading at $479000.0 for FY2025, 46.54% down from the prior year.
  • Current Deferred Revenue was $479000.0 for Q4 2025 at Vivos Therapeutics, down from $538000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $4.1 million in Q2 2021 and troughed at $479000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $2.4 million (2021), against an average of $2.2 million.
  • Year-over-year, Current Deferred Revenue surged 35.14% in 2021 and then plummeted 79.73% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.4 million in 2021, then increased by 26.64% to $3.0 million in 2022, then fell by 20.11% to $2.4 million in 2023, then crashed by 63.08% to $896000.0 in 2024, then tumbled by 46.54% to $479000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Current Deferred Revenue are $479000.0 (Q4 2025), $538000.0 (Q3 2025), and $485000.0 (Q2 2025).